1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc.

6785.TWO
Alar Pharmaceuticals Inc.TW flagTaipei Exchange
117.00
TWD
-0.50
- -
7.82BMarket Cap
Alar Pharmaceuticals Inc.
6785.TWO
(Taipei Exchange)

Recent

price

117.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.1
0.02
- -
0.01
- -
0.01
8.23
0.09
- -
0.04
Revenue per Share
-3.44
-1.96
-1.94
-2.86
-1.13
-0.35
6.71
0.27
- -
-1.2
Basic EPS, GAAP
-24.33
-1.52
-1.98
-2.85
-1.14
-0.6
6.97
-1.14
- -
-2.62
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
1.49
- -
- -
Dividend per Share
3.37
6.04
2.78
3.5
1.94
9.03
15.74
13.08
- -
11.8
Book Value per Share
1.42
9.06
5.46
11.99
9.37
9.03
15.74
37.03
- -
36.26
Tangible Book Value per Share
6
27
35
50
57
57
57
67
- -
66
Basic Weighted Avg Shares
1
- -
- -
1
- -
1
469
6
3
3
Sales/Revenue/Turnover
-3,451
-14,188.6
- -
-28,460.83
- -
-5,815.88
82.15
-1,168.02
-6,095.1
-6,095.1
Operating Margin (%)
2
2
3
3
3
3
3
4
5
5
Depreciation Expense
-21
-54
-68
-143
-64
-20
383
18
-80
-80
Net Income, GAAP
- -
- -
- -
- -
- -
- -
2.17
50.96
- -
- -
Effective Tax Rate (%)
-3,448.83
-10,753.6
- -
-23,799.5
- -
-2,483.88
81.53
312.36
-2,894.41
-2,894.41
Profit Margin (%)
1
242
180
587
524
492
828
2,387
2,278
2,278
Working Capital
- -
- -
2
1
- -
1
- -
- -
- -
- -
LT Debt
20
259
191
599
534
515
897
2,492
2,403
2,403
Total Equity
- -
- -
- -
- -
- -
- -
51.48
-1.91
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
54.06
2.04
- -
- -
Return on Capital (%)
- -
-57.89
-51.72
-105.03
-45.09
-6.36
54.21
2.04
-9.59
-9.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
2
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
67
67
Market Capitalization
9,356
15,541
20,146

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
2,394
2,379
2,353
Cash, Cash Equivalents & STI
2,360
2,339
2,296
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
74
90
74
Payables & Accruals
- -
- -
- -
ST Debt
2
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.82%
-3.56%
Free Cash Flow
- -
-271.84%
127.32%
Net Income, GAAP
- -
-556.67%
-538.54%
Sales/Revenue/Turnover
- -
- -
-52.67%
Total Cash Common Dividend
- -
- -
-83.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
1
468
469
2024
- -
- -
6
- -
6
2025
- -
1
- -
2
3

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.29
-0.17
0.03
- -
6.71
2024
0.19
-0.05
-0.22
- -
0.27
2025
-0.03
-0.38
-0.41
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1.49
2025
- -
- -
- -
- -
- -
Similar Companies
Formosa Laboratories, Inc. (4746.TW)
New Nordic Healthbrands AB (NNH.ST)
PharmaResearch Co., Ltd. (214450.KQ)
POZEN Inc. (POZN)
Bloomios, Inc. (BLMS)
Pharmaron Beijing Co., Ltd. (3759.HK)
Business
Alar Pharmaceuticals Inc. is a biotechnology company specializing in the development of long-acting injectable drug products targeting central nervous system (CNS) disorders and chronic diseases. Its core product offerings include long-acting formulations for opioid use disorder, chronic pain, and major depressive disorder, employing proprietary depot technology characterized by low viscosity solution, small injection volumes, and sustained drug release profiles. The company develops drugs such as ALA-1000, a sustained-release injectable buprenorphine prodrug designed for treatment-resistant opioid use disorder with dosing intervals potentially extending to three months. Alar Pharmaceuticals operates primarily in Taiwan with market reach extending to America, Europe, and Asia. Founded in 2016 and headquartered in Taichung, Taiwan, the company also engages in contract manufacturing services within the pharmaceutical sector. Recent major developments include an exclusive global licensing agreement signed in October 2023 with Indivior PLC, whereby Indivior obtained rights to develop, manufacture, and commercialize Alar’s long-acting injectable buprenorphine portfolio, including ALA-1000, except for China, Hong Kong, Taiwan, and Macau. This agreement involved upfront payments totaling $15 million to Alar, plus potential milestone payments tied to regulatory and commercial achievements. Additionally, Alar has received patents covering its sustained-release formulations, valid until 2037 and 2039, and recently in 2025 secured patent grant notifications in Vietnam and Europe for its long-acting injectable ketamine pamoate salts, supporting its pipeline expansion in treatment-resistant depression therapies. The firm has advanced clinical trials with its ALA-3000 extended-release ketamine injection, reflecting a strategic focus on expanding treatment options for CNS disorders with novel delivery technologies. Thus, Alar Pharmaceuticals Inc. is positioned as a niche player in developing innovative long-acting injectable CNS therapeutics, advancing partnerships and patent protections while maintaining operations centered in Taiwan with international collaborations and markets.